SCHEMBL16795696

SCHEMBL16795696

CC(=O)c1cc2cccc(Cl)c2o1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
RECQL P46063 1/20 0.62
CHRNA7 P36544 1/20 0.45
ALDH1A1 P00352 6/20 0.45
KMT2A Q03164 4/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.44
BRCA1 P38398 1/20 0.44
CASP7 P55210 1/20 0.44
STAT3 P40763 3/20 0.43
PDE7B Q9NP56 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6237938 0.84 DAO (0.48) LMNARECQLCHRNA7ALDH1A1KMT2A
SCHEMBL1896215 0.82 LMNA (0.66) LMNARECQLALDH1A1KMT2AMAOA
SCHEMBL10648590 0.81 LMNA (0.64) LMNARECQLALDH1A1KMT2AMAOA
SCHEMBL30950193 0.79 LMNA (0.62) LMNARECQLCHRNA7ALDH1A1KMT2A
SCHEMBL4856085 0.79 LMNA (0.62) LMNARECQLCHRNA7ALDH1A1KMT2A
SCHEMBL1287575 0.79 LMNA (0.62) LMNARECQLALDH1A1KMT2AMAOA
SCHEMBL6241107 0.79 CHRNA7 (0.51) CHRNA7ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL18313394 0.79 CHRNA7 (0.43) LMNARECQLCHRNA7ALDH1A1KMT2A
SCHEMBL16119578 0.79 MAOB (0.72) KMT2AMAOAMAOBKDM4EGAA
SCHEMBL17842824 0.79 MAOB (0.51) LMNARECQLALDH1A1KMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
WO-2016201168-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF FORUM PHARMCEUTICALS INC. (US) 2016-12-15 WO disclosed
WO-2015087094-A1 NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF PSEN2, SMN1; SMN2, OTC LMNA 2961/4885RECQL 418/4885CHRNA7 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.